Skip to main content

Advertisement

SpringerLink
Log in

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

To evaluate the association between the timing of best tumor shrinkage (bTS) and metastatic renal cell carcinoma (mRCC) patient survival after first-line tyrosine kinase inhibitor (TKI) therapy.

Methods

The tumors of 91 patients with mRCC showed a response to TKIs. None of the patients had received prior cytokine therapy. The magnitude of bTS was categorized according to the Response Evaluation Criteria in Solid Tumors v. 1.1. The patients were divided into two subgroups according to the timing of bTS: early responders (≤3 months) and late responders (>3 months). Overall survival (OS) and progression-free survival (PFS) after first-line TKI therapy were evaluated, and factors predicting survival were examined.

Results

Sunitinib, sorafenib, and pazopanib were used in 62, 25, and 4 responders, respectively. In total, 52 (57.1 %) and 39 (42.9 %) patients were early and late responders, respectively. Early responders had significantly lower PFS compared to late responders (median survival, 11.4 vs. 19.1 months; log-rank test, p = 0.0263), although there were no significant differences in the OS of early and late responders (27.0 vs. 30.1 months, p = 0.306). Multivariate analyses revealed that the timing of bTS was an independent predictor of PFS and OS (PFS, hazard ratio 4.09, p < 0.0001; OS, hazard ratio 2.32, p = 0.0107).

Conclusion

The timing of bTS was an independent predictor of survival in patients with mRCC who received first-line TKIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

bTS:

Best tumor shrinkage

mRCC:

Metastatic renal cell carcinoma

TKI:

Tyrosine kinase inhibitor

OS:

Overall survival

PFS:

Progression-free survival

RECIST:

The standard response evaluation criteria in solid tumors

AE:

Adverse events

HR:

Hazard ratios

CI:

Confidence intervals

MSKCC:

Memorial Sloan Kettering Cancer Center

References

  1. Figlin R, Sternberg C, Wood CG (2012) Novel agents and approaches for advanced renal cell carcinoma. J Urol 188:707–715

    Article  CAS  PubMed  Google Scholar 

  2. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  CAS  PubMed  Google Scholar 

  3. Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731

    Article  CAS  PubMed  Google Scholar 

  4. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  CAS  PubMed  Google Scholar 

  5. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxf) 1990;45:228–247

  6. Busch J, Seidel C, Goranova I et al (2014) Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer (Oxf) 1990;50:563–569

  7. Grunwald V, McKay RR, Krajewski KM et al (2015) Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67:952–958

    Article  PubMed  PubMed Central  Google Scholar 

  8. Seidel C, Busch J, Weikert S et al (2013) Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer 109:2998–3004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miyake H, Miyazaki A, Imai S et al (2016) Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan. Target Oncol 11:175–182

    Article  PubMed  Google Scholar 

  10. Molina AM, Lin X, Korytowsky B et al (2014) Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer (Oxf) 1990;50:351–358

  11. Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406

    Article  PubMed  Google Scholar 

  12. Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924

    Article  PubMed  Google Scholar 

  13. Kondo T, Takagi T, Kobayashi H et al (2014) Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma–comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol 44:270–277

    Article  PubMed  Google Scholar 

  14. Ishihara H, Kondo T, Omae K et al (2016) The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 46:568–574

    Article  Google Scholar 

  15. Heng DY, Wells JC, Rini BI et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66:704–710

    Article  PubMed  Google Scholar 

  16. Conti SL, Thomas IC, Hagedorn JC et al (2014) Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 134:2245–2252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    CAS  PubMed  Google Scholar 

  18. Zhang HL, Qin XJ, Wang HK et al (2015) Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget 6:36870–36883

    PubMed  PubMed Central  Google Scholar 

  19. Iacovelli R, Lanoy E, Albiges L et al (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110:1747–1753

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Editage (www.editage.jp) for English language editing.

Author information

Authors and Affiliations

  1. Department of Urology, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Hiroki Ishihara, Takafumi Yagisawa, Tsunenori Kondo, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi & Kazunari Tanabe

Authors
  1. Hiroki Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takafumi Yagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsunenori Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Omae
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshio Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junpei Iizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirohito Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazunari Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsunenori Kondo.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ishihara, H., Yagisawa, T., Kondo, T. et al. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. Int J Clin Oncol 22, 126–135 (2017). https://doi.org/10.1007/s10147-016-1032-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-016-1032-7

Keywords

Search

Navigation